Abstract
In July 2008, icatibant (Firazyr; Jerini), a bradykinin B2 receptor antagonist, was granted market authorization by the European Commission for the symptomatic treatment of acute attacks of hereditary angioedema.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Davis, A. E. 3rd. New treatments addressing the pathophysiology of hereditary angioedema. Clin. Mol. Allergy 6, 2 (2008).
Gompels, M. M. et al. C1 inhibitor deficiency: consensus document. Clin. Exp. Immunol. 139, 379–394 (2005).
Nussberger, J. et al. Plasma bradykinin in angio-oedema. Lancet 351, 1693–1697 (1998).
Marceau. F. & Regoli, D. Bradykinin receptor ligands: therapeutic perspectives. Nature Rev. Drug Discov. 3. 845–852 (2004).
Hock, F. J. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102, 769–773 (1991).
Wirth, K. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102, 774–777 (1991).
European Medicines Agency (EMEA). European Public Assessment Report – Firazyr. EMEA web site [online], (2008).
Bork, K. et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 19, 1497–1503 (2007).
Bork, K. et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am. J. Med. 120, 987–992 (2007).
Bork, K. et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45, 1774–1784 (2005).
Schneider, L. et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416–422 (2007).
Choi, G. et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 47, 1028–1032 (2007).
IMS Health Analysis, IMS MIDAS Quantum (2008).
Hilliker, I. et al. Jerini (Credit Suisse Securities Europe, 27 Feb 2008).
White, B. Jerini (Deutsche Bank Biotechnology, 1 May 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
K.B. was closely involved in the conduct of clinical trials with icatibant.
Rights and permissions
About this article
Cite this article
Bork, K., Yasothan, U. & Kirkpatrick, P. Icatibant. Nat Rev Drug Discov 7, 801–802 (2008). https://doi.org/10.1038/nrd2694
Issue date:
DOI: https://doi.org/10.1038/nrd2694
This article is cited by
-
A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE)
Clinical Reviews in Allergy & Immunology (2016)
-
New insights into the stereochemical requirements of the bradykinin B2 receptor antagonists binding
Journal of Computer-Aided Molecular Design (2016)
-
Currently available treatments and future treatment options for hereditary angioedema
Allergo Journal (2015)
-
Currently available treatments and future treatment options for hereditary angioedema
Allergo Journal International (2015)
-
Current Management Options for Hereditary Angioedema
Current Allergy and Asthma Reports (2012)
